Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.

Williams JH, Hutmacher MM, Zierhut ML, Becker JC, Gumbiner B, Spencer-Green G, Melia LA, Liao KH, Suster M, Yin D, Li R, Meng X.

Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579. doi: 10.1111/bcp.13094. Epub 2016 Sep 22.

2.

A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.

Cohen S, Emery P, Greenwald M, Yin D, Becker JC, Melia LA, Li R, Gumbiner B, Thomas D, Spencer-Green G, Meng X.

Br J Clin Pharmacol. 2016 Jul;82(1):129-38. doi: 10.1111/bcp.12916. Epub 2016 Apr 29.

3.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, OrdoƱez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

4.

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

Damjanov N, Kauffman RS, Spencer-Green GT.

Arthritis Rheum. 2009 May;60(5):1232-41. doi: 10.1002/art.24485. Erratum in: Arthritis Rheum. 2009 Oct;60(10):3071.

6.

ANA+ (anti-nuclear antibody) is correlated with RF+ (rheumatoid factor) in rheumatoid arthritis.

Matsos MP, Pope JE, Spencer-Green G.

Inflammopharmacology. 2004;12(3):229-31. No abstract available.

PMID:
15527547
7.

Correction regarding adalimumab labelling.

Spencer-Green G.

Clin Infect Dis. 2004 Oct 15;39(8):1257. No abstract available.

PMID:
15486862
8.

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results.

Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT.

J Rheumatol. 2003 Apr;30(4):691-6.

PMID:
12672185
9.

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK.

Arthritis Rheum. 2002 Jun;46(6):1443-50.

10.

Immune function in patients with rheumatoid arthritis treated with etanercept.

Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW.

Clin Immunol. 2002 Apr;103(1):13-21.

PMID:
11987981
11.

Etanercept (Enbrel): update on therapeutic use.

Spencer-Green G.

Ann Rheum Dis. 2000 Nov;59 Suppl 1:i46-9. Review.

12.

Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: how physicians manage treatment failures.

Spencer-Green G, Spencer-Green E.

J Rheumatol. 1998 Nov;25(11):2088-93.

PMID:
9818649
14.

Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies.

Spencer-Green G, Alter D, Welch HG.

Am J Med. 1997 Sep;103(3):242-8. Review.

PMID:
9316557
15.

Low dose etodolac in rheumatoid arthritis: a review of early studies.

Spencer-Green G.

J Rheumatol Suppl. 1997 Feb;47:3-9; discussion 48-50.

PMID:
9035014
16.

The evolution of Raynaud's phenomenon: a longterm prospective study.

Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G.

J Rheumatol. 1995 Dec;22(12):2226-32.

PMID:
8835553
17.

Retinoic acid effects on endothelial cell function: interaction with interleukin 1.

Spencer-Green G.

Clin Immunol Immunopathol. 1994 Jul;72(1):53-61.

PMID:
8020193
18.

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF.

J Exp Med. 1994 Jul 1;180(1):341-6.

19.

A novel assay to measure plasminogen activation capacity in tissue culture on concanavalin A-sepharose.

Spencer-Green G.

Thromb Res. 1994 Jun 15;74(6):665-72. No abstract available.

PMID:
8091407
20.

Radiologic vignette. X-linked hypophosphatemia (familial vitamin D-resistant rickets).

Yost JH, Spencer-Green G, Brown LA.

Arthritis Rheum. 1994 Mar;37(3):435-8. No abstract available.

PMID:
8129801
21.
22.

Drug treatment of arthritis. Update on conventional and less conventional methods.

Spencer-Green G.

Postgrad Med. 1993 May 15;93(7):129-40. Review.

PMID:
8493195
23.
24.

Diagnosis and management of vascular disease in systemic sclerosis.

Yost JH, Spencer-Green G.

Compr Ther. 1993;19(2):53-9. Review.

PMID:
8370246
25.

Serologic testing only part of Lyme diagnosis.

Yost JH, Spencer-Green G.

J Am Osteopath Assoc. 1992 Oct;92(10):1218-20. No abstract available.

PMID:
1459869
26.

Prospective study of the evolution of Raynaud's phenomenon.

Fitzgerald O, Hess EV, O'Connor GT, Spencer-Green G.

Am J Med. 1988 Apr;84(4):718-26.

PMID:
3261127
27.

Hypothenar hammer syndrome: an occupational cause of Raynaud's phenomenon.

Spencer-Green G, Morgan GJ, Brown L, FitzGerald O.

J Rheumatol. 1987 Oct;14(5):1048-51.

PMID:
3430509
28.

Esophageal motility studies in patients with Raynaud's phenomenon.

Fitzgerald OM, Bongiovanni G, Hess EV, Merhar G, Fernandez-Ulloa M, Spencer-Green G.

J Rheumatol. 1987 Apr;14(2):273-7.

PMID:
3598996
29.

Nailfold capillaroscopy in type I diabetics with vasculopathy and limited joint mobility.

Trapp RG, Soler NG, Spencer-Green G.

J Rheumatol. 1986 Oct;13(5):917-20.

PMID:
3820201
30.

Polynucleotide antibodies in connective tissue disease: viral markers or disease mediators?

Spencer-Green G, Kelley L, Adams LE, Donovan-Brand R, Hess EV.

J Lab Clin Med. 1986 Feb;107(2):159-65.

PMID:
2418139
31.

Familial alterations of immunoregulation in systemic lupus erythematosus.

Spencer-Green G, Adams LE, Hurtubise P, Kravatz G, Hess EV.

J Rheumatol. 1985 Jun;12(3):498-503.

PMID:
2931520
32.

T-lymphocyte subset phenotypes: a multisite evaluation of normal subjects and patients with AIDS.

La Via MF, Hurtubise PE, Parker JW, Rubin RH, Burdash NM, Spencer-Green G, Bishop DA, Dziurzynski B.

Diagn Immunol. 1985;3(2):75-82.

PMID:
3930126
33.

Nailfold capillary abnormalities in childhood rheumatic diseases.

Spencer-Green G, Schlesinger M, Bove KE, Levinson JE, Schaller JG, Hanson V, Crowe WE.

J Pediatr. 1983 Mar;102(3):341-6.

PMID:
6827403
34.

Raynaud phenomenon.

Spencer-Green G.

Bull Rheum Dis. 1983;33(5):1-8. Review. No abstract available.

PMID:
6370363
35.

Nailfold capillary abnormalities and clinical outcome in childhood dermatomyositis.

Spencer-Green G, Crowe WE, Levinson JE.

Arthritis Rheum. 1982 Aug;25(8):954-8.

PMID:
7115454
36.

A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis.

Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA Jr, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV.

Arthritis Rheum. 1982 Jun;25(6):601-11.

PMID:
7092960
37.

A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death.

Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA Jr, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV.

Arthritis Rheum. 1982 Jun;25(6):612-7.

PMID:
7046757
38.

Congenital heart block and connective tissue disease.

Hess EV, Spencer-Green G.

Ann Intern Med. 1979 Oct;91(4):645-6. No abstract available.

PMID:
484970
39.
40.

Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis).

Maricq HR, Spencer-Green G, Leroy EC.

Bibl Anat. 1975;13:248-9. No abstract available.

PMID:
1231740

Supplemental Content

Loading ...
Support Center